GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives

Worldwide prevalence of type 2 diabetes mellitus (T2DM) and obesity has heightened the need to find treatments that control hyperglycemia, together with weight gain and resultant organ damage. Under this arrangement, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents. They act through both intra- and extrapancreatic pathways to promote glucose-dependent insulin secretion, lower glucagon concentrations, slow stomach emptying, and control circuits of cerebral appetite. This helps the body regulate blood glucose levels, leading to clinically significant weight loss. In addition to regulating metabolism, strong cardiovascular and renal outcome trial data (including STEP, SELECT, and FLOW) suggest that they can lower the disease burden of serious cardiovascular events and protect kidney functioning. It means they are disease-modifying agents. Other barriers include their high cost, gastrointestinal side effects, injectable formulations, and lack of long-term safety information, although they are an effective intervention for achieving greater use. Recently, novel agents such as oral semaglutide, dual and triple incretin agonists (tirzepatide, retatrutide), and drug-based combinations with sodium-glucose cotransporter-2 (SGLT2) have revolutionized the treatment of the disease and improved its clinical utility. Individualized optimization of treatment using precision medicine, in the form of tailored behavior, with respect to phenotypes and comorbidities, holds promise to enhance outcomes. The combination of glycemic control, long-term weight loss, and organ protection is shifting the approach to cardiac, renal, and other organ health, leveraging the action of GLP-1 receptor agonists.